Renaissance Technologies’s MiNK Therapeutics INKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,400
Closed -$116K 3457
2025
Q4
$116K Sell
10,400
-4,200
-29% -$54.2K ﹤0.01% 2984
2025
Q3
$204K Buy
+14,600
New +$234K ﹤0.01% 3128
2025
Q1
Sell
-10,171
Closed -$70.9K 3640
2024
Q4
$70.9K Sell
10,171
-498
-5% -$3.39K ﹤0.01% 3335
2024
Q3
$80K Sell
10,669
-2,115
-17% -$17.9K ﹤0.01% 3289
2024
Q2
$121K Buy
12,784
+2,261
+21% +$22K ﹤0.01% 3148
2024
Q1
$96K Buy
10,523
+1,319
+14% +$12.2K ﹤0.01% 3379
2023
Q4
$98K Buy
9,204
+3,434
+60% +$35.8K ﹤0.01% 3304
2023
Q3
$63K Sell
5,770
-8,783
-60% -$143K ﹤0.01% 3352
2023
Q2
$306K Buy
14,553
+13,523
+1,313% +$271K ﹤0.01% 3115
2023
Q1
$20K Buy
+1,030
New +$22.3K ﹤0.01% 3821
2022
Q2
Sell
-2,576
Closed -$58K 4398
2022
Q1
$58K Sell
2,576
-934
-27% -$28.1K ﹤0.01% 3886
2021
Q4
$157K Buy
+3,510
New +$417K ﹤0.01% 3593

Other funds holding INKT

Renaissance Technologies's INKT Position: Q1 2026 in Review

Renaissance Technologies sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 10,400 shares — an estimated $116K sold.

Renaissance Technologies first reported a position in INKT in Q4 2021 and held it in 12 quarters. The position peaked at $306K in Q2 2023. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Renaissance Technologies reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 10,400 MiNK Therapeutics shares in Q1 2026, an estimated $116K.
  • Renaissance Technologies first reported a position in MiNK Therapeutics in Q4 2021 and held it in 12 quarters.
  • Renaissance Technologies's MiNK Therapeutics position peaked at $306K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.